Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. - Wikidata - awgldk - TriplyDB

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

http://www.wikidata.org/entity/Q37151995

about

MIA is a potential biomarker for tumour load in neurofibromatosis type 1 Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis Malignant peripheral nerve sheath tumours in inherited disease Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients.Intrathoracic malignant peripheral nerve sheath tumors: imaging features and implications for management.Non-optic glioma in adults and children with neurofibromatosis 1.Emerging genotype-phenotype relationships in patients with large NF1 deletions.Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.Massive Soft Tissue Neurofibroma (Elephantiasis Neuromatosa): Case Report and Review of Literature.Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.Pediatric whole-body MRI: A review of current imaging techniques and clinical applications.Whole-body magnetic resonance imaging in children: technique and clinical applications.Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.Growth behavior of plexiform neurofibromas after surgery.Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.The Characteristics of 76 Atypical Neurofibromas as Precursors to Neurofibromatosis 1 Associated Malignant Peripheral nerve Sheath Tumors.A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands.Interactive segmentation of plexiform neurofibroma tissue: method and preliminary performance evaluation.Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis.Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions.Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice.Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.Familial spinal neurofibromatosis due to a multiexonic NF1 gene deletion

P2860

Q21245252-00536F87-3987-47B9-803C-BEB0507CA65C Q28730289-6A4FFDE3-4416-4656-B76F-EB8D2889B40F Q30460786-3213882E-2163-455B-A507-2C53D9E6C307 Q33711291-0EDAAC37-F653-45E9-B496-7B28F01E01A4 Q33737662-73DCBF9C-2624-44A6-B5F5-0CB070BA8811 Q33900906-A4AF9419-837C-44C2-98CB-B065488B2D8D Q36473944-5960E2FD-D8F3-4F4A-8264-980061C2DD30 Q37130298-B9E597DC-16CF-4F40-BE86-16CE64493629 Q37198259-ADE7EED9-E78B-45AC-B44A-CCAB100FAB93 Q37225398-B27C82EE-372A-40B0-94C9-54C4E68F4C7A Q37645352-86C91F8F-FC82-4980-970B-6E469F3E51D3 Q37725901-78CD2AF6-2312-40B7-923B-6DED745127A6 Q37737382-6E9C4B09-F9B9-415A-8C25-C1CA6038E6D4 Q37965376-4D705256-A566-4295-8DFA-740B5371EB1B Q38360990-0136F886-4471-4A6F-906D-64DB50014DFE Q38738733-F45FD70C-BF91-4FEC-8124-4F08E9DF4C0B Q38797784-9E5AD61F-7947-4EE3-985E-D33ECDDE8500 Q38845271-7C9FAAF1-71E2-4D41-8EEC-43A33F4DBFF0 Q38928320-1745DD80-0A61-4502-9479-B4B0396D2FFA Q39031599-7771AEC1-7CC5-4DAE-BAE5-CA81E29185BC Q42322248-F12CAC3E-0BB3-4BB7-AF74-7564077FC2FC Q43851945-803055F4-2C89-49B4-BE9C-216D50EE5217 Q45860563-85F15D28-D353-4F42-8ACE-8AE2A16D2BBF Q47793357-C185C2CD-DA77-49CB-A839-58FAA6FCE55C Q48510261-0DF7A34F-2059-4663-AC82-4FF806EC021D Q50855771-6DCC4ED6-0396-44A8-B328-BB91333C4D92 Q51353907-869BECEF-9F56-4935-A8CE-5736C2507F63 Q51607398-B93D50CB-78B2-4793-BDA0-5FD60D5B5679 Q51783578-B9BBC773-A634-488A-BE44-BC533F3A354C Q52983394-160C8C8D-35B4-4461-8E13-0A0A3777A7C2 Q53167800-F60E992F-BA72-46A5-9B87-D43DCD6172A4 Q53534584-C9D077C3-57FC-4B80-8DE3-4D71E40DE834 Q58193301-97FBCC6A-8763-4333-BB33-5F8C34F7C848

P2860

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

http://www.wikidata.org/entity/Q37151995

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@en

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@nl

type

label

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@en

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@nl

prefLabel

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@en

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@nl

P1433

Q37151995-D1B6E233-595C-40F8-8A79-50093D39F548

P1476

Q37151995-6051A261-BE87-4D5A-94F2-156FF00F9360

P2093

Q37151995-1CB973D4-8135-43DB-A90E-1D9FFD72BC96

Q37151995-2D77C53A-F46A-4444-B49F-1DE996D36017

Q37151995-314EFC41-4C6A-4318-9DD3-259BC240BF4C

Q37151995-A63281AB-C1DF-4720-A693-6CC62AA22FF9

Q37151995-AD52FC68-70B6-4F33-B6C1-FC0DFC0C6ED0

Q37151995-C2CB0A9C-0D09-4F22-96AF-7FCED3D521C8

Q37151995-CAB6DAB1-0C5F-41A6-B598-01EE59745494

P2860

Q37151995-0DDC6DFD-01A5-4FB3-9536-30EC527D898E

Q37151995-13A297B8-8A22-4B1A-896A-3410E36E6BC3

Q37151995-275348B3-DF39-44C9-A08E-3ABE7F2F795D

Q37151995-304E4724-502A-4E20-AA7C-8C28684A53E9

Q37151995-4187DA3D-2EEE-4E76-917E-A2B9E773C298

Q37151995-4B236ACD-40B9-4876-8FC5-F11467B25343

Q37151995-5BF7A4BD-1AFC-44CD-93E1-2B93A24F0BDC

Q37151995-6018B393-E870-4BB8-BB89-8A661E635881

Q37151995-66F1CD9D-AF1C-4BD8-8BE8-7293CF8D255C

Q37151995-6AE969F3-92DB-4680-BA88-35AB4CE8DDF5

P304

Q37151995-A64311DE-3834-497A-B967-008A8D8860EB

P31

Q37151995-8A17AD54-5FAF-40A5-8E98-90403D454622

P356

Q37151995-BA996200-8BF9-4A0C-B48E-05E6948F1C1D

P433

Q37151995-8D6C55D9-68D1-4234-B5AD-24E6866D8AC4

P478

Q37151995-202CDBDE-0CEE-4DED-8CC1-0B7CF4E0811D

P50

Q37151995-25868A84-CD5A-4D03-B647-F75CD64A4073

P577

Q37151995-528785B2-87A3-4B20-A8CF-3BAF8D57B1B7

P5875

Q37151995-F5575943-5F47-43E2-A546-9CC1427B361C

P698

Q37151995-212A1D38-12AC-442A-9941-0858B59253D3

P921

Q37151995-69B83D86-E6D4-4046-9C46-BB856A5DC71C

P932

Q37151995-641D1C6B-08C2-4B62-802C-8154B68A86CA

P356

15228517-2008-011

P1433

P1476

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

@en

P2093

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Carsten Fünsterer

http://www.w3.org/2001/XMLSchema#string

Eva Dombi

http://www.w3.org/2001/XMLSchema#string

Florence A Asuagbor

http://www.w3.org/2001/XMLSchema#string

Lan Kluwe

http://www.w3.org/2001/XMLSchema#string

Ralf Wenzel

http://www.w3.org/2001/XMLSchema#string

Victor-F Mautner

http://www.w3.org/2001/XMLSchema#string

P2860

High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

NF1 mutations and molecular testing

Clinical manifestations and management of neurofibromatosis type 1.

Elevated risk for MPNST in NF1 microdeletion patients.

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Genetics of neurofibromatosis 1 and the NF1 gene.

Clinical features and pathobiology of neurofibromatosis 1.

P304

593-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/15228517-2008-011

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5296692

http://www.w3.org/2001/XMLSchema#string

P698

18559970

http://www.w3.org/2001/XMLSchema#string

P921

P932

2666233

http://www.w3.org/2001/XMLSchema#string